APA (7th ed.) Citation

A, C., JE, G., MC, A., L, L., E, D., A, B., . . . A, R. (2025). Validation of Manhattan risk to predict aGvHD severity in Rapamycin and PTCy-based prophylaxis: A study on 459 consecutive HCT patients. Bone marrow transplantation, 60(10), 1394. https://doi.org/10.1038/s41409-025-02677-0

Chicago Style (17th ed.) Citation

A, Criscimanna, et al. "Validation of Manhattan Risk to Predict AGvHD Severity in Rapamycin and PTCy-based Prophylaxis: A Study on 459 Consecutive HCT Patients." Bone Marrow Transplantation 60, no. 10 (2025): 1394. https://doi.org/10.1038/s41409-025-02677-0.

MLA (9th ed.) Citation

A, Criscimanna, et al. "Validation of Manhattan Risk to Predict AGvHD Severity in Rapamycin and PTCy-based Prophylaxis: A Study on 459 Consecutive HCT Patients." Bone Marrow Transplantation, vol. 60, no. 10, 2025, p. 1394, https://doi.org/10.1038/s41409-025-02677-0.